The role of ROS in cancer is complex, with studies demonstrating both pro- and anti-tumor effects. In a pancreatic ductal adenocarcinoma model, ROS limitation through TIGAR has been shown to initially support cancer development but to later become a metabolic liability in metastasizing cells that is counteracted by decreased TIGAR expression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ccell.2020.01.009 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!